{{Rsnum
|rsid=11666638
|Chromosome=19
|position=34120844
|Orientation=plus
|GMAF=0.2704
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 12.4 | 43.4 | 44.2
| HCB | 2.9 | 28.5 | 68.6
| JPT | 7.1 | 27.4 | 65.5
| YRI | 12.9 | 35.4 | 51.7
| ASW | 5.3 | 45.6 | 49.1
| CHB | 2.9 | 28.5 | 68.6
| CHD | 3.7 | 41.3 | 55.0
| GIH | 5.9 | 44.6 | 49.5
| LWK | 9.1 | 38.2 | 52.7
| MEX | 7.0 | 28.1 | 64.9
| MKK | 20.5 | 48.7 | 30.8
| TSI | 9.8 | 42.2 | 48.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11666638
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.31, combined P value= 2.49E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470220
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11666638
|overall_frequency_n=40
|overall_frequency_d=128
|overall_frequency=0.3125
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=34
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}